Meyka Pro banner
NanoRepro AG

NanoRepro AG (XETRA: NN6.DE) Stock Competitors & Peer Comparison

See NN6.DE's competitors and their performance on the XETRA and across the wider stock market.

NN6.DE●XETRA
HealthcareMedical - Diagnostics & Research
€1.60
€0.04(2.74%)
German Market opens in 44h 29m

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for NN6.DE and its XETRA peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NN6.DE€1.60-2.74%22.2M-10.67-€0.15N/A
TN8.DE€597.40-2.19%220.9B33.36€17.91+0.27%
DAP.DE€202.80-2.87%142.6B36.63€5.54+0.66%
ILU.DE€124.28+0.60%18.8B29.38€4.23N/A
QIA.DE€45.05+0.26%9.3B22.01€2.05+5.36%
SYAB.DE€11.06-0.18%2.4B27.65€0.40+2.98%
MYD.DE€26.72+0.00%2.2B-256.92-€0.10N/A
ECX.DE€0.70-11.17%612.6K-0.04-€19.55N/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Thermo Fisher Scientific Inc. (XETRA: TN8.DE)

NN6.DE vs TN8.DE Comparison October 2026

NanoRepro AG (XETRA: NN6.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NN6.DE stands at 22.2M. In comparison, TN8.DE has a market cap of 220.9B. Regarding current trading prices, NN6.DE is priced at €1.60 on the XETRA, while TN8.DE trades at €597.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NN6.DE currently has a P/E ratio of -10.67, whereas TN8.DE's P/E ratio is 33.36. In terms of profitability, NN6.DE's ROE is -0.05%, compared to TN8.DE's ROE of +0.13%. Regarding short-term risk, NN6.DE is more volatile compared to TN8.DE. This indicates higher risk in terms of short-term price fluctuations for NN6.DE.Check TN8.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions